Objective
To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.
Management group
Pharmakon Advisors
Launch date
27/03/2017
Domicile
United Kingdom
Fund manager
Pedro Gonzalez de Cosio, Pablo Legorreta, Martin Friedman
Dividend frequency
Quarterly
Wind-up provisions
The Company has been established with an indefinite life, the Articles provide that a continuation vote be put to Shareholders (i) at the first AGM of the Company to be held following the fifth anniversary of Initial Admission and, if passed, at the AGM of the Company held every third year thereafter; and (ii) within two months of the expiration of any 12 month rolling period where the Shares have, on average, traded at a discount in excess of 10%. The next continuation vote will take place in 2025.
Market Cap (m) Total assets (m) Price (last close) NAV Discount / premium (%) Gearing (%) Dividend yield (%) Dividend dates Ongoing charge (%)
1,024.04 1,212.37 0.84 0.99 -15.53 0 8.33 Mar, Jun, Sep, Dec 1.1 (31/12/2023)
Scroll

Dividends

Dividends declared in last 12 months

Ex-Dividend date Payment date Dividend amount Special dividend Financial year
28/03/2024 30/04/2024 0.018 No 2024
15/02/2024 15/03/2024 0.018 No 2023
15/02/2024 15/03/2024 0.012 Yes 2023
07/12/2023 05/01/2024 0.018 No 2023
07/12/2023 05/01/2024 0.020 Yes 2023
Scroll

Performance (%)

Return type 1 year 3 years 5 years 10 years
BioPharma Credit Share price total return 2.6 22.3 30.1 N/A
Debt - Direct Lending AIC sector Share price total return -0.5 6.0 18.3 N/A
Scroll

Share structure

Number of shares
1,219,099,795

Traded volumes (number of shares)

  Yesterday 1 month 1 year 5 years
Total 3,457,461 44,600,882 398,166,801 1,916,954,027
Average N/A 2,179,340 1,577,730 1,519,660
Scroll

Traded values (m)

  Yesterday 1 month 1 year 5 years
Total 2.90 39.14 350.13 1,833.12
Average N/A 1.91 1.39 1.45
Scroll

Trading details

ISIN TIDM Traded currency Stock exchange
GB00BDGKMY29 BPCR USD London Stock Exchange - MAIN
Chi-x Europe Limited
London Stock Exchange
Scroll

Top holdings

Data as at : 30/11/2023

Investment % of total assets
Collegium 20.9
Insmed 13.6
LumiraDx 11.5
Coherus 11.4
BioCryst 11.3
BMS 7.4
OptiNose 6.5
UroGen 4.6
Evolus 4.6
ImmunoGen 2.3

Morningstar logo Data provided by Morningstar.

FE fundinfo logo Company documents provided by FE fundinfo.